Castle Biosciences (CSTL) Projected to Post Earnings on Monday

Key Points

• Castle Biosciences (CSTL) is set to announce its Q2 2025 earnings on August 4th, projecting a loss of ($0.44) per share and revenue of $71.53 million.
• Shares of CSTL have recently traded down 2.2%, with a market cap of $463.94 million and a price-to-earnings ratio of -84.58.
• Analysts have a consensus rating of "Buy" for CSTL, with target prices ranging from $35.00 to $42.00, indicating potential market optimism despite mixed earnings reports.

Castle Biosciences (NASDAQ:CSTL - Get Free Report) is expected to be issuing its Q2 2025 quarterly earnings data after the market closes on Monday, August 4th. Analysts expect the company to announce earnings of ($0.44) per share and revenue of $71.53 million for the quarter. Castle Biosciences has set its FY 2025 guidance at EPS.

Castle Biosciences (NASDAQ:CSTL - Get Free Report) last posted its quarterly earnings results on Monday, May 5th. The company reported ($0.20) earnings per share for the quarter, missing analysts' consensus estimates of ($0.08) by ($0.12). Castle Biosciences had a negative net margin of 1.46% and a positive return on equity of 3.41%. The business had revenue of $87.99 million during the quarter, compared to analysts' expectations of $80.40 million. On average, analysts expect Castle Biosciences to post $0 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

Castle Biosciences Price Performance

Shares of Castle Biosciences stock traded down $0.38 during trading on Thursday, reaching $15.70. The company's stock had a trading volume of 145,260 shares, compared to its average volume of 440,191. The business has a 50 day moving average price of $18.06 and a 200-day moving average price of $20.70. The company has a quick ratio of 9.19, a current ratio of 9.37 and a debt-to-equity ratio of 0.02. The company has a market capitalization of $453.26 million, a P/E ratio of -82.74 and a beta of 1.10. Castle Biosciences has a 12-month low of $15.45 and a 12-month high of $35.84.

Analyst Upgrades and Downgrades

A number of research firms have commented on CSTL. Lake Street Capital decreased their target price on Castle Biosciences from $40.00 to $35.00 and set a "buy" rating on the stock in a research report on Tuesday, May 6th. Canaccord Genuity Group decreased their target price on Castle Biosciences from $42.00 to $37.00 and set a "buy" rating on the stock in a research report on Tuesday, May 6th. Finally, Scotiabank decreased their target price on Castle Biosciences from $44.00 to $40.00 and set a "sector outperform" rating on the stock in a research report on Wednesday, May 21st. Eight equities research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock has a consensus rating of "Buy" and an average target price of $37.00.

Institutional Trading of Castle Biosciences

Institutional investors and hedge funds have recently made changes to their positions in the stock. Jones Financial Companies Lllp increased its stake in Castle Biosciences by 10,592.0% in the first quarter. Jones Financial Companies Lllp now owns 2,673 shares of the company's stock valued at $54,000 after purchasing an additional 2,648 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its stake in Castle Biosciences by 4.4% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 15,441 shares of the company's stock valued at $309,000 after purchasing an additional 655 shares during the last quarter. AQR Capital Management LLC increased its stake in Castle Biosciences by 548.9% in the first quarter. AQR Capital Management LLC now owns 137,022 shares of the company's stock valued at $2,743,000 after purchasing an additional 115,907 shares during the last quarter. Finally, Amundi increased its stake in Castle Biosciences by 15,811.5% in the first quarter. Amundi now owns 4,137 shares of the company's stock valued at $79,000 after purchasing an additional 4,111 shares during the last quarter. 92.60% of the stock is currently owned by hedge funds and other institutional investors.

About Castle Biosciences

Castle Biosciences, Inc, a molecular diagnostics company, provides testing solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus, uveal melanoma, and mental health conditions. It offers DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test to identify the risk of metastasis for patients diagnosed with invasive cutaneous melanoma; DecisionDx-SCC, a proprietary risk stratification GEP test for patients with cutaneous squamous cell carcinoma; MyPath Melanoma, a test used for patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a spatial omics test to predict future development of high-grade dysplasia and/or esophageal cancer in patients with non-dysplastic, indefinite dysplasia, or low-grade dysplasia Barrett's esophagus.